CAJ | 학술논문

目的：观察泽菲单药姑息治疗老年晚期胰腺癌的近期临床疗效和毒性反应。方法35例Ⅲ～Ⅳ期NSCLC 患者均经病理组织学或细胞学检查确诊，卡式评分＞50分，生存期超过3个月，采用国产吉西他滨（泽菲）单药化疗。结果35例患者均可评价疗效， CR 1例（2．5％），PR 8例（22．8％），SD10例（28．5％），PD16例（45．7％），有效率（CR＋PR）为25．7％。中位生存期MST 6．8个月，中位疾病进展时间 TTP 5．4个月，1年生存率33％。主要毒性反应为骨髓抑制和消化道反应。结论吉西他滨单药姑息治疗老年晚期胰腺癌疗效确切，可明显改善患者生存质量、延长生存时间、毒副反应轻可耐受。
목적：관찰택비단약고식치료노년만기이선암적근기림상료효화독성반응。방법35례Ⅲ～Ⅳ기NSCLC 환자균경병리조직학혹세포학검사학진，잡식평분＞50분，생존기초과3개월，채용국산길서타빈（택비）단약화료。결과35례환자균가평개료효， CR 1례（2．5％），PR 8례（22．8％），SD10례（28．5％），PD16례（45．7％），유효솔（CR＋PR）위25．7％。중위생존기MST 6．8개월，중위질병진전시간 TTP 5．4개월，1년생존솔33％。주요독성반응위골수억제화소화도반응。결론길서타빈단약고식치료노년만기이선암료효학절，가명현개선환자생존질량、연장생존시간、독부반응경가내수。
Objective To evaluate the recent clinical efficacy and toxicity of gemcitabine in the treatment of patients with advanced pancreatic cancer.Methods Thirst-five cases with advanced pancreatic cancer stagingⅢandⅣ, with KPS>50 and survival time longer than three months, were treated with gemcitabine.Results The efficacy of the 35 ca-ses can be evaluated.CR was 2.5%, PR was 22.8%, SD was 28.5%, PD was 45.7%.The response rates(RR)were 25.7%, myelosuppression and digestive tract reaction were the main toxicity.Median survival time was 6.8 months, time to progression was 5.4 months.One year survival rate was 33%.Conclusions Single gemcitabine is a good regi-men with low toxicity.